FREDERICK, Md.—The biopharmaceutical company MedImmune is expanding its Frederick manufacturing plant.
Frederick city and county officials joined the company in celebrating the official opening Friday of a 337,000-square-foot addition.
The new space expands production capacity for products including Synagis, a drug that prevents a respiratory virus infection in high-risk children.
Gaithersburg, Md.-based MedImmune says it employs about 250 people in Frederick and expects to add more.
The company is a subsidiary of London-based AstraZeneca PLC.